Join Growin Stock Community!

Neuphoria therapeutics inc.NEUP.US Overview

US StockHealthcare
(No presentation for NEUP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NEUP AI Insights

NEUP Overall Performance

NEUP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NEUP Recent Performance

2.41%

Neuphoria therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

NEUP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NEUP Key Information

NEUP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NEUP Profile

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Price of NEUP

NEUP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NEUP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.49
PB Ratio
1.87
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-37.79%
Revenue Growth (YoY)
2161.41%
Profit Growth (YoY)
9296.48%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.01
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.49
PB Ratio
1.87
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-37.79%
Revenue Growth (YoY)
2161.41%
Profit Growth (YoY)
9296.48%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NEUP's latest earnings report released?

    The most recent financial report for Neuphoria therapeutics inc. (NEUP) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NEUP's short-term business performance and financial health. For the latest updates on NEUP's earnings releases, visit this page regularly.

  • How is NEUP's revenue growth?

    In the latest financial report, Neuphoria therapeutics inc. (NEUP) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does NEUP have?

    At the end of the period, Neuphoria therapeutics inc. (NEUP) held Total Cash and Cash Equivalents of 22.25M, accounting for 0.61 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NEUP's EPS continuing to grow?

    According to the past four quarterly reports, Neuphoria therapeutics inc. (NEUP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NEUP?

    Neuphoria therapeutics inc. (NEUP)'s Free Cash Flow (FCF) for the period is -6.44M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 91.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.